HELQ and cancer: Conversely, RAD52–driven MiDAS in cancer cells may be adapted to prevent chromosome mis-segregation, potentially impacting CFS expression, unlike the synergistic effect of HELQ and FANCD2 in promoting ICL repair [49,59].